Breaking News, Collaborations & Alliances

Biogen Idec, MAKScientific In MS Pact

MAKScientific eligible to receive as much as $34 million

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec and MAKScientific, LLC have entered into an exclusive, worldwide option and collaboration agreement to develop and commercialize drug candidates for the treatment of multiple sclerosis (MS) and other neurodegenerative diseases. Biogen Idec has an option for an exclusive license to select MAKScientific’s discovery drug candidates for all indications worldwide. If Biogen exercises this option, MAKScientific will be eligible to receive an exercise fee of as much as $3 million and as mu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters